The drug is employed in the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal, junction adenocarcinoma) whose tumours overexpress the HER2 gene (HER2+) [38]. This evidence concerns the gene ERBB2 and neoplasm.